Indian J Dermatol Venereol Leprol 2021 May-Jun;87(3):455
Department of Dermatology and Venereology All India Institute of Medical Sciences, New Delhi, India.
J Clin Microbiol 2021 Jul 28:JCM0114921. Epub 2021 Jul 28.
Microbial Pathogenesis Laboratory, Infection Medicine, Edinburgh Medical School (Biomedical Sciences), University of Edinburgh, Edinburgh, United Kingdom.
Clonal multidrug resistance recently emerged in , complicating the therapeutic management of this difficult-to-treat animal and human pathogenic actinomycete. The currently spreading multidrug-resistant (MDR) "2287" clone arose in equine farms upon acquisition, and co-selection by mass macrolide-rifampin therapy, of the pRErm46 plasmid carrying the (46) macrolides-lincosamides-streptogramins resistance determinant, and an mutation. Here, we screened a collection of susceptible and macrolide-rifampin-resistant from equine clinical cases using a panel of 15 antimicrobials against rapidly growing mycobacteria (RGM), nocardiae and other aerobic actinomycetes (NAA). Read More
Sci Rep 2021 Jul 23;11(1):15136. Epub 2021 Jul 23.
RIKEN Center for Biosystems Dynamics Research, 6-2-3 Furuedai, Suita, Osaka, 565-0874, Japan.
Drug-resistant tuberculosis (TB) is a growing public health problem. There is an urgent need for information regarding cross-resistance and collateral sensitivity relationships among drugs and the genetic determinants of anti-TB drug resistance for developing strategies to suppress the emergence of drug-resistant pathogens. To identify mutations that confer resistance to anti-TB drugs in Mycobacterium species, we performed the laboratory evolution of nonpathogenic Mycobacterium smegmatis, which is closely related to Mycobacterium tuberculosis, against ten anti-TB drugs. Read More
Antimicrob Agents Chemother 2021 Jul 19:AAC0070621. Epub 2021 Jul 19.
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China.
TB47, a new drug candidate targeting QcrB in the electron transport chain, has shown a unique synergistic activity with clofazimine and formed a highly sterilizing combination. Here, we investigated the sterilizing effects of several all-oral regimens containing TB47 + clofazimine + linezolid as a block and the roles of fluoroquinolones and pyrazinamide in them. All these regimens cured tuberculosis within 4 to 6 months in a well-established mouse model and adding pyrazinamide showed significant difference in bactericidal effects. Read More
BMC Public Health 2021 Jul 16;21(1):1404. Epub 2021 Jul 16.
KNCV Tuberculosis foundation, The Hague, The Netherlands.
Background: BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. The objective of this study was to assess the acceptability, feasibility, and likelihood of implementing BPaL in Indonesia, Kyrgyzstan, and Nigeria. Read More
J Glob Antimicrob Resist 2021 Jun 29. Epub 2021 Jun 29.
National Tuberculosis Reference Laboratory, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. Electronic address:
Objectives: New anti-TB drugs delamanid and bedaquiline appear as the last line to defense drug-resistant tuberculosis. Understanding the background prevalence of resistance to new drugs can help predict the lifetime of these drugs' effectiveness and inform regimen design.Methods: TB strains without prior exposure to novel anti-TB drugs were analyzed retrospectively. Read More